Natixis Advisors LLC Invests $879,000 in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Natixis Advisors LLC acquired a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,968 shares of the company's stock, valued at approximately $879,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its holdings in Apogee Therapeutics by 121.6% in the third quarter. Victory Capital Management Inc. now owns 346,358 shares of the company's stock valued at $20,345,000 after buying an additional 190,092 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in Apogee Therapeutics in the third quarter valued at about $499,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Apogee Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,655 shares of the company's stock worth $508,000 after purchasing an additional 3,371 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock worth $94,000 after purchasing an additional 285 shares in the last quarter. Finally, Waypoint Capital Advisors LLC purchased a new position in shares of Apogee Therapeutics during the 3rd quarter worth approximately $36,835,000. Institutional investors and hedge funds own 79.04% of the company's stock.

Insider Buying and Selling at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $47.62, for a total transaction of $1,904,800.00. Following the transaction, the chief executive officer now owns 1,394,487 shares in the company, valued at approximately $66,405,470.94. The trade was a 2.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total transaction of $374,972.90. Following the transaction, the insider now owns 274,128 shares in the company, valued at $15,422,441.28. The trade was a 2.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 114,995 shares of company stock worth $6,128,295 in the last quarter. 36.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

APGE has been the subject of a number of recent research reports. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research note on Monday. They set a "buy" rating and a $89.00 price objective for the company. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research note on Monday. They issued a "buy" rating and a $89.00 target price for the company. Guggenheim lifted their target price on shares of Apogee Therapeutics from $95.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Wedbush reaffirmed an "outperform" rating and issued a $87.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics has a consensus rating of "Buy" and an average price target of $83.50.

Apogee Therapeutics Trading Up 1.7 %

Shares of APGE traded up $0.74 during mid-day trading on Thursday, reaching $44.70. The company had a trading volume of 549,708 shares, compared to its average volume of 494,664. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -18.47 and a beta of 2.93. The firm has a fifty day simple moving average of $53.83 and a 200-day simple moving average of $48.54. Apogee Therapeutics, Inc. has a fifty-two week low of $16.39 and a fifty-two week high of $72.29.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.